Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Administration of Cariprazine (30 µg/kg) reduces the striatal uptake of both radioligands to the level of nonspecific binding compared with baseline PET measurements
inhibiting Cdc28p and Pho85p (IC50s = 7 and 2 µM
Chemical Name: 3-(cyclopropylmethoxy)-N-(3
21-12(20)19-11)6-5-8-1-2-8/h3-4
Ruxolitinib sulfate - CAS# 1092939-16-6 alog 2 Administration of Cariprazine (30 µg/kg)Ruxolitinib sulfate is the first potent, selective JAK1 2 inhibitor to enter the clinic with IC50s of 3. 3 nM 2. 8 nM, and has > 130 fold selectivity for JAK1 2 versus JAK3. Ruxolitinib potently and selectively inhibits JAK2V617F mediated signaling and proliferation, markedly increases apoptosis in a dose dependent manner, and at 64 nM results in a doubling of cells with depolarized mitochondria in Ba F3 cells. Ruxolitinib demonstrates remarkable
US$ 172.00
US$ 48.00
US$ 34371.62
US$ 29.00
US$ 28.00
US$ 4658.98
US$ 4444.61
US$ 28.00
US$ 48.00